EGF and lung carcinoma: Early phase I trial was conducted to evaluate the effect of CIMAvax-EGF on the prevention of lung cancer development in high-risk patients, like family history of lung cancer or chronic pulmonary obstructive disease, or recurrence in patients with stage IB to IIIA NSCLC (Clinical Trial number: NCT04298606).